Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies

被引:2
|
作者
Kim, Inho
Yoon, Sung Soo
Lee, Kyung-Hun
Keam, Bhumsuk
Kim, Tae Min
Kim, Jin-Soo
Kim, Hoon-Gu
Oh, Myoung-Don
Han, Kyou-Sup
Park, Myoung Hee
Park, Seonyang
Kim, Byoung Kook
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul 110744, South Korea
关键词
allogeneic stem cell transplantation; hematological malignancy; reduced intensity conditioning; youths;
D O I
10.1111/j.1399-0012.2006.00512.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
We have conducted a direct comparison of the outcomes of reduced intensity and myeloablative conditioning in younger adults with hematological malignancies < 50 yr. One hundred and five patients received transplants from human leukocyte antigen (HLA)-matched donors, via either reduced intensity (n = 35) or myeloablative conditioning (n = 70). The median ages of the reduced intensity and myeloablative groups were 36 and 33 yr (p = 0.014). Neutrophil engraftment (i.e. time to absolute neutrophil count > 0.5 x 10(9)/L) occurred more rapidly in the reduced intensity group (median: 10 d; range: 0-21 d) than in the myeloablative group (median: 18 d; range: 11-38 d; p < 0.0001). The incidence of grades 2-4 acute graft-vs.-host disease were similar between the reduced intensity and myeloablative groups, at 17% vs. 24% respectively (p = 0.40). The cumulative incidence of day 100 non-relapse mortality was 18% in the reduced intensity group, and 21% in the myeloablative group (p = 0.88). The overall two-yr survival rates were 43% in the reduced intensity group, and 35% in the myeloablative group (p = 0.72). In conclusion, reduced intensity transplantation yielded outcomes comparable with those of myeloablative transplantation in patients under 50 with hematological malignancies.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 50 条
  • [31] Oral mucositis (OM) and outcomes of allogeneic (AL) hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies.
    Vera-Lionch, M
    Oster, G
    Ford, C
    Lu, J
    Khazanov, I
    Sonis, S
    BLOOD, 2005, 106 (11) : 874A - 875A
  • [32] Duration of ulcerative mucositis (OM) and outcomes of allogeneic (AL) hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies
    Sonis, S
    Vera-Llonch, M
    Ford, C
    Lu, J
    Khazanov, I
    Oster, G
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 23 - 23
  • [33] Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation
    Koreth, John
    Antin, Joseph H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 364 - 366
  • [34] Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies
    Lin, Richard J.
    Elko, Theresa A.
    Devlin, Sean M.
    Shahrokni, Armin
    Jakubowski, Ann A.
    Dahi, Parastoo B.
    Perales, Miguel-Angel
    Tamari, Roni
    Shaffer, Brian C.
    Sauter, Craig S.
    Papadopoulos, Esperanza B.
    Gyurkocza, Boglarka
    Korc-Grodzicki, Beatriz
    Barker, Juliet N.
    Maloy, Molly A.
    Giralt, Sergio A.
    BONE MARROW TRANSPLANTATION, 2020, 55 (01) : 157 - 164
  • [35] Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies
    Richard J. Lin
    Theresa A. Elko
    Sean M. Devlin
    Armin Shahrokni
    Ann A. Jakubowski
    Parastoo B. Dahi
    Miguel-Angel Perales
    Roni Tamari
    Brian C. Shaffer
    Craig S. Sauter
    Esperanza B. Papadopoulos
    Boglarka Gyurkocza
    Beatriz Korc-Grodzicki
    Juliet N. Barker
    Molly A. Maloy
    Sergio A. Giralt
    Bone Marrow Transplantation, 2020, 55 : 157 - 164
  • [36] Outcomes after Second Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies
    Huselton, Eric
    Slade, Michael
    Abboud, Camille
    Cashen, Amanda
    DiPersio, John F.
    Ghobadi, Armin
    Pusic, Iskra
    Romee, Rizwan
    Uy, Geoffrey L.
    Vij, Ravi
    Westervelt, Peter
    Schroeder, Mark A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S278 - S278
  • [37] Comparison of the outcomes following conventional hematopoietic stem cell transplantation (HSCT) vs. reduced-intensity stem cell transplantation (RIST) in older patients with hematologic malignancies.
    Kojima, R
    Kami, M
    Tanaka, Y
    Kusumi, E
    Kanda, Y
    Mori, S
    Yoshioka, S
    Tajima, K
    Fujisawa, S
    Kariamori, H
    Morishima, S
    Sao, H
    Kasai, M
    Kasai, M
    Taniguchi, S
    Sakamaki, H
    Hirai, H
    Harada, M
    Takaue, Y
    BLOOD, 2003, 102 (11) : 732A - 732A
  • [38] Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
    Majd A. El-Harasis
    Mehrdad Hefazi
    Raghav Julakanti
    William J. Hogan
    Mark R. Litzow
    Mrinal M. Patnaik
    Joerg Herrmann
    Bone Marrow Transplantation, 2021, 56 : 508 - 510
  • [39] Allogeneic stem cell transplantation after non myeloablative conditioning for poor risk patients with hematologic malignancies.
    Dentamaro, T
    Cudillo, L
    Picardi, A
    Rainaldi, A
    Cox, MC
    Catalano, GF
    Adorno, G
    Piccioni, D
    Masi, M
    Tamburini, A
    Buccisano, F
    Amadori, S
    BONE MARROW TRANSPLANTATION, 1998, 21 : S101 - S101
  • [40] Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
    El-Harasis, Majd A.
    Hefazi, Mehrdad
    Julakanti, Raghav
    Hogan, William J.
    Litzow, Mark R.
    Patnaik, Mrinal M.
    Herrmann, Joerg
    BONE MARROW TRANSPLANTATION, 2021, 56 (02) : 508 - 510